Intravascular Papillary Endothelial Hyperplasia (IPEH)

Intravascular Papillary Endothelial Hyperplasia (IPEH) is a benign (non-cancerous) growth that forms inside a blood vessel. It appears when the inner lining cells of a vessel—called endothelial cells—overgrow while the body is trying to heal a blood clot. Doctors also call it Masson’s tumor. It can look scary and is sometimes mistaken for a cancer of blood vessels (angiosarcoma), but it does not spread and is curable with simple surgery in most cases. BioMed CentralPMC

Intravascular Papillary Endothelial Hyperplasia (IPEH) is a non-cancerous growth that forms inside a blood vessel when the body is trying to heal a blood clot. Think of it as an over-enthusiastic repair job. After a small bleed or clot happens in a vein (or sometimes in a pre-existing vascular lesion like a hemangioma), the endothelial cells (the thin lining cells inside blood vessels) start to grow to organize and clean up the clot. In IPEH, these cells grow into soft little finger-like fronds (papillae) around the clot. Because this repair growth can be bulky, it becomes a small, firm lump. It can look worrying and is often mistaken for a cancer such as angiosarcoma, but it is not cancer. With complete surgical removal, it usually does not come back.

• Intravascular = inside a blood vessel (a vein or, less often, an artery).

• Papillary = forming tiny finger-like fronds or folds.

• Endothelial = made of endothelial cells, the thin lining on the inside of every blood vessel.

• Hyperplasia = extra growth of normal cells (not cancer). Think of it as healing turned up too high.

When a small clot forms in a vein, your body tries to organize and recanalize it (create new channels for blood to flow). During that repair job, the endothelial lining can sprout papillary fronds into the clot. If this reaction is exuberant, a tidy little ball of papillary tissue grows within the vessel lumen—that is IPEH. This is why many pathologists call IPEH a reactive process rather than a true tumor. BioMed CentralPMC

Types

IPEH comes in three classic types. The types are about where the lesion arises and what was there before:

1. Primary (Pure) IPEH
   Forms de novo (on its own) inside a dilated blood vessel, usually a vein. This is the most common pattern in the skin and subcutis of the hand/head/neck.
   Key idea: a clot inside a normal vessel → repair overshoots → IPEH. PMC

2. Secondary (Mixed) IPEH
   Develops on top of a pre-existing vascular lesion (for example, a hemangioma, venous malformation, or pyogenic granuloma).
   Key idea: there’s already a vascular abnormality; a clot forms within it, and the same repair overshoot creates IPEH. PMC

3. Extravascular (Hematoma-related) IPEH
   The least common form. Occurs outside a vessel, within a blood clot (hematoma) in the soft tissue after trauma.
   Key idea: blood leaked into tissue (a bruise/hematoma); endothelial-like sprouts grow into the clot, making papillary nests. PMC

---

Causes

Honest note: Doctors don’t believe IPEH has a single, direct “cause” like an infection or gene mutation. It is best understood as a healing reaction to local clotting. So the items below are things that can make a small vessel clot or get injured, which then may lead to IPEH in a small minority of people. Many cases still have no clear trigger.

1. Local trauma or blunt injury to soft tissue → small hematoma or intravascular clot.

2. Repetitive minor trauma (e.g., tool use with fingers) → micro-clots in small veins.

3. Pre-existing hemangioma (a benign vessel tumor) where thrombosis can occur.

4. Venous malformation/varix (abnormally dilated vein) encouraging stasis and clot.

5. Pyogenic granuloma (lobular capillary hemangioma) that thromboses internally.

6. Arteriovenous malformation with turbulent flow → endothelial injury/clot.

7. Varicose veins or chronic venous stasis in limbs.

8. Recent surgery in the area causing vessel injury or post-op hematoma.

9. Needle puncture or injection leading to local vessel injury.

10. Compression from casts, tight bands, or masses → decreased flow → clot risk.

11. Hypercoagulable states (genetic or acquired) that make clots more likely.

12. Pregnancy (temporarily pro-coagulant state).

13. Estrogen-containing contraception or hormone therapy (mild ↑ clot risk).

14. Smoking (damages endothelium; promotes clotting).

15. Prolonged immobility (long travel/bedrest) → sluggish venous flow.

16. Dehydration (relative blood “thickening” → micro-clots).

17. Inflammation or vasculitis injuring vessel lining locally.

18. Prior radiation to the area (rarely, can cause vascular changes and thrombosis).

19. Local infection causing phlebitis (vein inflammation) and clot.

20. Idiopathic (no obvious trigger) — still common.

Core to almost all cases is a thrombus and recanalization/organization with papillary endothelial overgrowth. Trauma and pre-existing vascular lesions are repeatedly reported contexts; the rest are general clot-promoters that may contribute in select patients. BioMed CentralPMC

---

Symptoms

Simple rule: Most IPEH lesions are small, slow-growing, well-circumscribed lumps near the skin, often painless, sometimes tender, and occasionally blue-red.

1. Small lump or nodule under or in the skin.

2. Slow growth over weeks to months.

3. No pain (common) or mild tenderness (especially with pressure).

4. Color change: bluish-red/purple hue from blood within/around the lesion.

5. Soft to firm on touch; often well-defined edges.

6. Moves slightly under the skin (if subcutaneous).

7. Occasional throbbing or fullness sensation.

8. Local swelling after use or minor trauma.

9. Surface warmth rarely (if inflamed).

10. Skin ulcer/bleeding is uncommon, but shallow bleeding may occur in oral/nasal sites.

11. Functional annoyance when on fingers/hand/foot (grip, shoes).

12. Cosmetic concern on face/head/neck.

13. Numbness/tingling only if it presses a nerve (uncommon).

14. Limited motion of a nearby joint if large (rare).

15. Anxiety due to fear of cancer (common reason to seek care).

Sites and look are consistent with reports emphasizing head/neck and upper extremities, especially digits; foot and other sites are less common but documented. BioMed CentralPMCfastracjournal.org

---

Diagnostic tests

Important: The gold standard test is microscopic examination of the removed lump (histopathology). Imaging helps plan surgery and avoid surprises. Blood tests rarely “diagnose” IPEH, but may be used to look for clotting tendencies or other causes in select patients.

A) Physical exam

1. Visual inspection
   Doctor looks for size, shape, color, and skin changes (bluish-red hue, ulcer, bleeding).

2. Gentle palpation
   Feeling the lump for consistency (soft/firm), mobility, tenderness, and edge definition—IPEH often feels well-circumscribed.

3. Blanching test (finger pressure)
   Light pressure may pale a vascular lesion (blanch) and refill when released—suggests blood-filled nature.

4. Transillumination (light test)
   A bright light behind the lump sometimes shows translucence if fluid/blood channels are present (not specific).

5. Regional comparison
   Checking nearby veins, lymph nodes, and joints to rule out other causes (varix, lymph node, ganglion).

6. Functional check
   Range-of-motion and strength of nearby joints/muscles (e.g., fingers) if the mass interferes with function.

B) Manual/bedside vascular and nerve checks

7. Capillary refill time
   Press nail/skin and time color return—normal in IPEH; helps exclude major arterial issues.

8. Provocative compression
   Gentle compression of the mass to see if size/firmness changes (suggests venous component).

9. Tinel-like percussion
   Tapping over the lesion to check for tingly nerve sensation—usually negative unless a nerve is irritated.

10. Allen’s test (hand lesions)
    Quick bedside test of arterial inflow to the hand—helps surgical planning if the mass is near vessels.

C) Laboratory & pathological tests

11. Histopathology (definitive test)
    After excision or biopsy, a pathologist sees papillary fronds covered by bland endothelial cells growing within the vessel/clot, often with signs of organizing thrombus. No significant atypia or necrosis. This pattern confirms IPEH. BioMed Central

12. Immunohistochemistry (IHC)
    Stains like CD31, CD34, factor VIII-related antigen, and often ERG highlight endothelial cells. Low Ki-67 (a growth marker) supports a benign process. These help confirm vascular origin and distinguish IPEH from angiosarcoma. PMC+1

13. H&E stain review with deeper levels
    Multiple slices ensure the lesion is intravascular/extravascular as described and lacks malignant features.

14. Thrombophilia screen (selected patients)
    If someone has multiple clots or strong family history, tests for hypercoagulable states may be ordered (e.g., Factor V Leiden). This does not diagnose IPEH but may explain why a clot formed.

15. Inflammatory markers (selected)
    If vasculitis/infection is suspected around the lesion, blood tests can support that context (again, not diagnostic of IPEH).

16. Basic labs
    Usually normal in IPEH; obtained pre-op for safety rather than for diagnosis.

D) Electrodiagnostic tests

17. Nerve conduction studies
    Only if the mass is suspected to compress a nerve (e.g., numb finger). This does not identify IPEH; it measures nerve function.

18. Electromyography (EMG)
    Same idea—used rarely to evaluate muscle/nerve irritation near a deep lesion.

E) Imaging tests

19. Ultrasound (US)
    First-line in many small, superficial lumps. Often shows a well-defined, mixed-echo soft-tissue mass with internal vascularity on Doppler. Helpful to distinguish a solid vascular lesion from a simple cyst and to guide biopsy if needed. PubMed+1

20. Color Doppler ultrasound
    Highlights blood flow patterns. IPEH can show intralessional flow; sometimes you’ll see channels corresponding to recanalized thrombus. PubMed

21. MRI (Magnetic Resonance Imaging)
    Excellent soft-tissue detail. Typical features include well-circumscribed mass, intermediate/low T1, high T2 signal with heterogeneous enhancement after contrast—reflecting papillary tissue and blood products. Useful for surgical planning and to rule out aggressive tumors. PubMed+1

22. MR with contrast (gadolinium)
    Shows enhancing papillary components and can reveal internal septa or organized thrombus.

23. CT scan
    Less sensitive than MRI for soft tissue, but used when MRI isn’t available/appropriate or to assess deep/complex sites.

24. Plain X-ray
    Usually normal; may show soft-tissue shadow. Rare calcifications (phleboliths) if long-standing thrombosis, though not typical.

25. CT or MR angiography
    If the lesion sits near major vessels or a vascular malformation, angiography maps arterial/venous anatomy before surgery.

26. Conventional catheter angiography (rare)
    Reserved for complex vascular malformations or when pre-op embolization is considered (unusual for IPEH).

27. Photo documentation
    Serial clinical photos to track size/color changes over time, especially if observation is chosen initially.

Treatment

Core truth: There is no pill that “shrinks” IPEH reliably. Complete surgical excision with clear margins is the definitive treatment for most cases. Observation may be reasonable for very small, symptom-free lesions in tricky areas, after a confident diagnosis.

Non-pharmacological treatments (therapies & measures)

(Description • Purpose • Mechanism — in plain English)

1. Watchful waiting (selected cases)
   Small, symptom-free lesions in awkward locations can be observed after imaging/biopsy confirms benign IPEH. Purpose: avoid unnecessary surgery. Mechanism: most IPEH are stable; no systemic risk.

2. Education & reassurance
   Clear explanation that it’s benign reduces anxiety. Purpose: informed decisions. Mechanism: corrects misperception of “cancer.”

3. Activity modification
   Avoid repetitive pressure/trauma over the lesion (e.g., tool handles). Purpose: limit tenderness and micro-bleeding. Mechanism: reduces mechanical irritation.

4. Protective padding/splints (hand/finger lesions)
   Soft finger sleeves or splints during tasks. Purpose: comfort and prevent trauma. Mechanism: disperses pressure.

5. Limb elevation (venous congestion)
   Intermittent elevation if swelling/congestion worsens discomfort. Purpose: symptom control. Mechanism: improves venous return, reduces fullness.

6. Compression therapy (if limb venous stasis/varicosities present)
   Graduated stockings. Purpose: reduce venous pooling and new micro-clots in the region. Mechanism: external pressure aids vein flow.

7. Local heat/warm compress for discomfort
   Short periods of gentle warmth. Purpose: comfort. Mechanism: relaxes tissues and may improve superficial venous flow.

8. Cold packs (brief, post-irritation)
   For tenderness after accidental bumps. Purpose: symptom relief. Mechanism: reduces neurogenic inflammation; use gently, wrapped.

9. Weight management (if obese)
   Purpose: reduce limb venous stasis. Mechanism: lowers venous pressure and systemic inflammation.

10. Smoking cessation
    Purpose: reduce clotting tendency and endothelial injury. Mechanism: removes pro-thrombotic/toxic exposure.

11. Optimize mobility & calf-muscle pumping
    Regular walking/ankle pumps. Purpose: better venous return. Mechanism: muscle pump action empties veins.

12. Treat underlying varicose veins/venous disease
    Referral for venous evaluation if symptoms/signs present. Purpose: reduce future micro-thrombi. Mechanism: fix the upstream stasis.

13. Skin care over lesion
    Emollients, avoid friction. Purpose: prevent chafing/bleeding from accidental grazes. Mechanism: improved barrier.

14. Ergonomic changes at work
    Padded grips/tools, frequent breaks. Purpose: protect lesion area. Mechanism: reduce repetitive micro-trauma.

15. Mind-body pain skills (if tender)
    Relaxed breathing, brief mindfulness. Purpose: reduce pain amplification. Mechanism: dampens central sensitization.

16. Post-op wound care education
    After excision: keep clean/dry as directed. Purpose: prevent infection and recurrence risks from poor healing. Mechanism: optimal healing environment.

17. Sun protection (if facial lesion post-excision)
    Sunscreen and hats. Purpose: minimize scar discoloration. Mechanism: UV avoidance improves scar outcome.

18. Hand therapy (if lesion or surgery near tendons)
    Guided range-of-motion after surgeon clears. Purpose: restore function. Mechanism: prevents stiffness/adhesions.

19. Psychological support (appearance anxiety)
    Counseling if visible facial/oral lesions affected confidence. Purpose: quality of life. Mechanism: coping strategies.

20. Shared decision-making
    Weighing observation vs. surgery vs. timing. Purpose: align with patient goals. Mechanism: informed consent and expectations.

 Drug treatments

Important: There is no proven medication that cures IPEH. Drugs are used for symptom control, peri-operative care, or treating complications. Doses below are typical adult ranges; follow your clinician’s advice.

1. Acetaminophen (Paracetamol) — Analgesic
   Dose/Time: 500–1000 mg every 6–8 h PRN (max per local guidance, often 3–4 g/day).
   Purpose: Pain relief if the lump is tender.
   Mechanism: Central COX inhibition; reduces pain/fever.
   Side effects: Generally safe at proper doses; liver toxicity if overdosed or with heavy alcohol.

2. NSAIDs (e.g., Ibuprofen, Naproxen) — Anti-inflammatory analgesics
   Dose/Time: Ibuprofen 200–400 mg every 6–8 h; Naproxen 220–500 mg twice daily.
   Purpose: Pain/tenderness control pre-op or if observing.
   Mechanism: COX inhibition → less prostaglandin-mediated pain/inflammation.
   Side effects: Stomach upset/ulcer, kidney strain, bleeding risk (use carefully if surgery planned).

3. Topical NSAIDs (diclofenac gel)
   Purpose: Local pain relief with lower systemic exposure.
   Mechanism: Local COX inhibition.
   Side effects: Skin irritation; avoid on broken skin/surgical wounds.

4. Short course antibiotics (only if secondary skin infection occurs)
   Class: Cephalexin, amoxicillin-clavulanate, etc., per local flora.
   Purpose: Treat post-trauma or post-op infection signs (redness, warmth, pus).
   Mechanism: Kills susceptible bacteria.
   Side effects: GI upset, allergy; use only with clinical signs of infection.

5. Local anesthetics (lidocaine) for procedures
   Purpose: Numbing for biopsy/excision.
   Mechanism: Sodium channel blockade.
   Side effects: Rare systemic toxicity if excessive dose; usually very safe.

6. Peri-operative analgesia (short-term opioids if needed)
   Purpose: Immediate post-op pain not controlled by NSAIDs/acetaminophen.
   Mechanism: μ-opioid receptor agonism.
   Side effects: Nausea, constipation, sedation; use lowest effective dose for shortest time.

7. Anticoagulants (not for IPEH itself; only for a separate clotting indication)
   Class: DOACs/warfarin/LMWH only if a clinician diagnoses a separate venous thrombosis.
   Purpose: Treat unrelated DVT/PE risk, not to “treat” IPEH.
   Mechanism: Inhibits coagulation pathways.
   Side effects: Bleeding; strictly specialist-guided.

8. Intralesional corticosteroid (rare, selected cases)
   Purpose: Sometimes tried for small vascular proliferations to reduce inflammation/size if surgery is difficult; evidence for IPEH is limited.
   Mechanism: Anti-inflammatory/anti-angiogenic effects.
   Side effects: Skin atrophy, hypopigmentation; use cautious, individualized.

9. Prophylactic antibiotics (peri-op as per surgeon)
   Purpose: Reduce surgical site infection risk in selected settings.
   Mechanism: Pre-incision coverage per protocol.
   Side effects: As above; targeted, short course.

10. Proton pump inhibitor (if NSAIDs required and GI risk is high)
    Purpose: Protect stomach during necessary NSAID use.
    Mechanism: Blocks gastric acid secretion.
    Side effects: Headache, rarely nutrient malabsorption with long use.

Not recommended: “Anti-cancer” chemotherapy, radiotherapy, or anti-angiogenic systemic drugs are not indicated for benign IPEH.

Dietary, molecular supplements

There is no supplement proven to treat or shrink IPEH. Some can support general vascular and wound health, especially after surgery, but they do not replace definitive care. Always clear supplements with your clinician (drug interactions, bleeding risk).

1. Vitamin C (ascorbic acid) — 250–500 mg/day. Supports collagen formation in wound healing; antioxidant.

2. Zinc — 15–30 mg/day (short term). Cofactor for tissue repair; excessive use can cause copper deficiency.

3. Protein (whey/food) — 20–40 g/day supplement if diet is low. Provides amino acids for healing.

4. Omega-3 (fish oil) — 1–2 g EPA+DHA/day. Anti-inflammatory; may increase bleeding at high doses (caution pre-op).

5. Vitamin D — per level (often 1000–2000 IU/day). Immune modulation; bone/overall health.

6. B-complex (esp. folate, B6, B12) — standard daily dose. Helps correct hyperhomocysteinemia if present.

7. Citrus bioflavonoids / Diosmin-Hesperidin — per label. May aid venous tone in chronic venous disease; limited evidence; not curative.

8. Gotu kola (Centella asiatica) — per label. Traditional use for microcirculation/wound support; evidence modest; avoid if anticoagulated.

9. Bromelain — 200–400 mg/day. Anti-inflammatory enzyme; bleeding risk with anticoagulants/antiplatelets.

10. Curcumin (turmeric extract) — 500–1000 mg/day with piperine. Anti-inflammatory; bleeding caution.

11. Pycnogenol (pine bark) — per label. Antioxidant; some data in venous insufficiency; not IPEH-specific.

12. Horse chestnut seed extract (aescin) — per label. May reduce leg swelling in venous disease; avoid if anticoagulated; liver caution.

13. Resveratrol — per label. Antioxidant/vascular signaling; human data limited; not IPEH-specific.

14. CoQ10 — 100–200 mg/day. Mitochondrial support; minimal bleeding risk; evidence general.

15. Probiotic (post-op antibiotic course) — as advised. Gut support if antibiotics used; not related to IPEH itself.

Bottom line: Supplements are adjuncts at best. They do not treat IPEH and some increase bleeding risk around surgery — always disclose them to your surgeon.

Regenerative / stem-cell” drugs

The user asked for these specifically, so here’s the straight truth:

• Stem cell therapies, growth factors, biologic immunomodulators, and “regenerative” injections have no evidence to treat IPEH and could be harmful (they might even stimulate unwanted vessel growth).

• Do not pursue these outside a regulated clinical trial (and such trials for IPEH are essentially nonexistent).

• The safest “regenerative” step is good surgical technique and healthy wound care, not biologic drugs.

If you saw claims online about “stem cells shrinking vascular tumors,” they do not apply to this benign, reactive lesion.

Surgery

1. Simple (complete) excision
   What: The surgeon removes the entire lump with a small margin of normal tissue.
   Why: Curative in most cases; provides tissue for definitive diagnosis.

2. Wide local excision (if recurrent/uncertain margins)
   What: A slightly larger margin around the lesion.
   Why: Reduces chance of recurrence when prior removal was incomplete or margins were close.

3. Microsurgical or function-preserving excision (hand/face)
   What: Careful dissection near nerves, tendons, ducts.
   Why: Keeps function and appearance while ensuring complete removal.

4. Endoscopic or laser-assisted excision (selected oral/airway/dermal sites)
   What: Minimally invasive visualization or laser cutting/coagulation as an adjunct.
   Why: Better access in tight spaces; hemostasis in vascular fields.

5. Excision combined with treatment of associated vascular anomaly
   What: If IPEH sits within a venous malformation/hemangioma, surgeons may also treat the parent lesion (e.g., sclerotherapy or staged management) based on a vascular team’s plan.
   Why: Limits future thrombosis and recurrence risk in that area.

Prevention

1. Protect areas prone to knocks (gloves, padding for hands).

2. Stop smoking (cut clotting/injury risks).

3. Healthy weight & regular walking (better venous return).

4. Manage varicose veins/venous disease (seek evaluation if symptomatic).

5. Avoid prolonged sitting/standing; take movement breaks.

6. Good ergonomic tools (padded grips to minimize micro-trauma).

7. Disclose estrogen therapy to your clinician if you have venous disease.

8. Control diabetes and blood pressure (protect vessels).

9. Be cautious with supplements that raise bleeding risk near procedures.

10. Follow post-op instructions exactly (reduces complications/recurrence).

When to see a doctor

• You notice a new lump anywhere, especially if it grows, changes color, becomes painful, or bleeds.

• A previously “diagnosed” benign lump begins to change quickly.

• You have venous issues (varicose veins, leg swelling) and new skin nodules.

• You need clearance before starting supplements or NSAIDs if surgery is likely.

• After excision, if you see redness, drainage, fever, or increasing pain.

What to eat and what to avoid

1. Eat a balanced, protein-rich diet (lean meats, legumes, dairy) to support healing.

2. Eat colorful fruits/vegetables (antioxidants) — berries, citrus, leafy greens.

3. Eat whole grains and hydrate well (circulation and recovery).

4. Include omega-3 foods (fish, walnuts) unless your surgeon advises restriction before surgery.

5. Limit ultra-processed, high-salt foods (fluid retention, inflammation).

6. Limit alcohol (impairs healing, interacts with pain meds).

7. Avoid starting new supplements before surgery without approval (bleeding risk).

8. Avoid heavy doses of garlic/ginger/ginkgo/turmeric/fish oil for 7–10 days pre-op unless cleared (potential bleeding effects).

9. If diabetic, keep glucose controlled for better wound healing.

10. After surgery, follow specific surgeon dietary advice if any (e.g., soft diet for oral lesions).

Frequently asked questions

1. Is IPEH cancer?
   No. It’s a benign overgrowth of normal vessel lining cells during clot organization.

2. Why does it form a lump?
   The repair tissue grows into papillary fronds around a clot, creating bulk inside the vessel.

3. Can it spread (metastasize)?
   No. It does not spread like cancer.

4. What is the best treatment?
   Complete surgical excision is usually curative.

5. Can I just leave it alone?
   Sometimes yes, if small and proven benign. Many choose excision for certainty/symptoms.

6. Will it come back after surgery?
   Rarely, usually only if margins were incomplete. A skilled excision minimizes risk.

7. Do I need chemotherapy or radiation?
   No. These are not used for IPEH.

8. Can medicines shrink it?
   No reliable medicines do that. Drugs are for pain control or surgical care.

9. How do doctors tell it apart from angiosarcoma?
   Pathology (microscope + immunostains) shows bland cells, thrombus, papillae, low proliferation, and clear borders.

10. Is it caused by my diet?
    No. Diet doesn’t cause it, though healthy eating supports post-op healing.

11. Can I exercise?
    Yes, but avoid direct trauma to the lesion. After surgery, follow return-to-activity guidance.

12. Is it genetic?
    Not typically. It’s linked to local clot/repair, not inherited syndromes.

13. Can it occur in the mouth or face?
    Yes. Head/neck and oral cavity are possible sites; careful, cosmetic-minded excision is common.

14. Do I need scans?
    Ultrasound/MRI help for deep/uncertain lesions or surgical planning; superficial, small lesions may go straight to excision/biopsy.

15. Who should treat me?
    Dermatologic surgeon, plastic surgeon, hand surgeon, ENT/oral & maxillofacial surgeon, or vascular team depending on location.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 08, 2025.

PDF Document For This Disease Conditions References